

研究成果の刊行に関する一覧：

1. 建石 良介, 小池和彦. クラウドを基盤としたガイドライン支援システムの開発と実装. 肝臓 2021;62(8): 512-15.
2. 河口義邦、國土典宏、長谷川潔. 【肝癌治療の最前線】SURF trial. 外科 82 卷 1223-1227, 2020
3. 長谷川 潔, 竹村 信行, 國土 典宏. 各分野のガイドラインを紐解く 肝癌診療ガイドライン(解説). 日本外科学会雑誌 121巻 356-358, 2020
4. 竹村 信行, 長谷川 潔, 國土 典宏. 【消化器悪性腫瘍診療におけるガイドラインの功罪】肝癌診療におけるガイドラインの功罪(解説/特集). 外科 82巻 629-634, 2020
5. 有田 淳一, 河口 義邦, 國土 貴嗣, 長谷川 潔ほか. 若手に役立つ議論・オピニオンリーダーからのメッセージ 早期(3cm3個以下)肝癌に対する治療 肝切除. 肝臓クリニカルアップデート 6巻 2189-4469, 2020
6. 島村拓司、長谷川潔、狩山和也、中野聖士ほか.【肝癌治療ガイドライン2017を再検証する】 肝臓 61巻 285-308, 2020
7. 島村拓司、長谷川潔、島田光生ほか. <総説>「肝癌治療ガイドライン2017を再検証する」を振り返って. 肝臓 61巻 309-313, 2020
8. 建石良介, 工藤正俊, 泉 並木, 村上卓道 肝細胞癌の診断アルゴリズム(肝癌診療マニュアル第4版) 一般社団法人日本肝臓学会(医学書院) - 82-84, 2020
9. Iida H, Tani M, Aihara T, Hasegawa K, et al. New metastasectomy criteria for peritoneal metastasis of hepatocellular carcinoma: A study of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 27 673-681, 2020
10. Kaibori M, Yoshii K, Hasegawa K, Kokudo N, et al. Impact of systematic segmentectomy for small hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 27 331-341, 2020
11. Tateishi R, Matsumura T, M, Araki E, Koike K, et al. Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. J Gastroenterol 56 261-273, 2021
12. Tateishi R, Matsumura T, Okanoue T, Koike K, et al. Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. J Gastroenterol 56 261-273, 2021
13. Sato M, Tateishi R, Yatomi Y, Koike K. Artificial intelligence in the diagnosis and management of hepatocellular carcinoma. J Gastroenterol Hepatol 36 551-560, 2021

14. Yamada T, Tateishi R, Koike K, Todo T, et al. Neoadjuvant Use of Oncolytic Herpes Virus G47Delta Enhances the Antitumor Efficacy of Radiofrequency Ablation. *Mol Ther Oncolytics* 18 535-545, 2020
15. Wake T, Tateishi R, Fukumoto T, Koike K, et al. Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume. *PLoS One* 15 e0231836, 2020
16. Fukumoto T, Minami T, Tateishi R, Koike K, et al. Chronological change in alpha-fetoprotein levels in hepatocellular carcinoma after eradication of hepatitis C virus. *Liver Int* 40 2305-2306, 2020
17. Asaoka Y, Tateishi R, Hayashi A, Koike K, et al. Expression of c-Met in Primary and Recurrent Hepatocellular Carcinoma. *Oncology* 98 186-194, 2020
18. Arita J, Yamamoto H, Kokudo T, Hasegawa K, Miyata H, Toh Y, Gotoh M, Kokudo N, Kakeji Y, Yasuyuki S. Impact of board certification system and adherence to the clinical practice guidelines for liver cancer on post-hepatectomy risk-adjusted mortality rate in Japan: A questionnaire survey of departments registered with the National Clinical Database. *J Hepatobiliary Pancreat Sci.* 2021 Oct; 28(10): 801-811. doi: 10.1002/jhbp.1000. Epub 2021 Jul 7. PMID: 34043880
19. Kawaguchi Y, Hasegawa K, Hagiwara Y, De Bellis M, Famularo S, Panettieri E, Matsuyama Y, Tateishi R, Ichikawa T, Kokudo T, Izumi N, Kubo S, Sakamoto M, Shiina S, Takayama T, Nakashima O, Murakami T, Vauthey JN, Giuliani F, De Carlis L, Romano F, Ruzzenente A, Guglielmi A, Kudo M, Kokudo N. Effect of Diameter and Number of Hepatocellular Carcinomas on Survival After Resection, Transarterial Chemoembolization, and Ablation. *Am J Gastroenterol.* 2021 Aug 1;116(8):1698-1708. doi: 10.14309/ajg.000000000001256. PMID: 33900211
20. Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. *Liver Cancer.* 2021

Jun;10(3):181-223. doi: 10.1159/000514174. Epub 2021 May 19. PMID: 34239808

21. Kawaguchi Y, Hasegawa K, Hagiwara Y, De Bellis M, Famularo S, Panettieri E, Matsuyama Y, Tateishi R, Ichikawa T, Kokudo T, Izumi N, Kubo S, Sakamoto M, Shiina S, Takayama T, Nakashima O, Murakami T, Vauthey JN, Giuliante F, De Carlis L, Romano F, Ruzzenente A, Guglielmi A, Kudo M, Kokudo N. Effect of Diameter and Number of Hepatocellular Carcinomas on Survival after Resection, Transarterial Chemoembolization, and Ablation. *Am J Gastroenterol* 2021;116(8): 1698-708. Epub:2021/04/27 doi: 10.14309/ajg.0000000000001256
22. Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Kubo S. Report of the 22nd Nationwide Follow-up Survey of Primary Liver Cancer in Japan (2012-2013). *Hepatol Res* 2022;52(1): 5-66. Epub:2021/05/30 doi: 10.1111/hepr.13675
23. Abe-Doi M, Murayama R, Komiyama C, Tateishi R, Sanada H. Effectiveness of Ultrasonography for Peripheral Catheter Insertion and Catheter Failure Prevention in Visible and Palpable Veins. *J Vasc Access* 2021: 11297298211022078. Epub:2021/06/03 doi: 10.1177/11297298211022078
24. Hangai S, Kawamura T, Kimura Y, Chang CY, Hibino S, Yamamoto D, Nakai Y, Tateishi R, Oshima M, Oshima H, Kodama T, Moriya K, Koike K, Yanai H, Taniguchi T. Orchestration of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment by Ubiquitous Cellular Protein Tctp Released by Tumor Cells. *Nat Immunol* 2021;22(8): 947-57. Epub:2021/07/10 doi: 10.1038/s41590-021-00967-5
25. Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: Jsh Consensus Statements and Recommendations 2021 Update. *Liver Cancer* 2021;10(3): 181-223. Epub:2021/07/10 doi: 10.1159/000514174
26. Fujiwara N, Kobayashi M, Fobar AJ, Hoshida A, Marquez CA, Koneru B, Panda G, Taguri M, Qian T, Raman I, Li QZ, Hoshida H, Sezaki H, Kumada H, Tateishi R, Yokoo T, Yopp AC, Chung RT, Fuchs BC, Baumert

- TF, Marrero JA, Parikh ND, Zhu S, Singal AG, Hoshida Y. A Blood-Based Prognostic Liver Secretome Signature and Long-Term Hepatocellular Carcinoma Risk in Advanced Liver Fibrosis. *Med (N Y)* 2021;2(7): 836-50 e10. Epub:2021/07/29 doi: 10.1016/j.medj.2021.03.017
27. Miki N, Inoue S, Shibahara H, Kurazono K, Perard R, Tateishi R. A Cost-Effectiveness Analysis of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease in Japan. *JGH Open* 2021;5(8): 879-87. Epub:2021/08/14 doi: 10.1002/jgh3.12597
28. Minami T, Tateishi R, Fujiwara N, Nakagomi R, Nakatsuka T, Sato M, Uchino K, Enooku K, Nakagawa H, Fujinaga H, Izumiya M, Hanajiri K, Asaoka Y, Kondo Y, Tanaka Y, Otsuka M, Ohki T, Arai M, Tanaka A, Yasuda K, Miura H, Ogata I, Kamoshida T, Inoue K, Koike Y, Akamatsu M, Mitsui H, Fujie H, Ogura K, Yoshida H, Wada T, Kurai K, Maekawa H, Obi S, Teratani T, Masaki N, Nagashima K, Ishikawa T, Kato N, Moriya K, Yotsuyanagi H, Koike K. Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after Hcv Eradication with Antivirals. *Liver Cancer* 2021;10(4): 309-19. Epub:2021/08/21 doi: 10.1159/000513705
29. Kurokawa R, Inui S, Tanishima T, Nakaya M, Kurokawa M, Ishida M, Gonoi W, Amemiya S, Nakai Y, Ishigaki K, Tateishi R, Koike K, Abe O. Incidence and Computed Tomography Findings of Lenvatinib-Induced Pancreatobiliary Inflammation: A Single-Center, Retrospective Study. *Medicine (Baltimore)* 2021;100(35): e27182. Epub:2021/09/04 doi: 10.1097/MD.00000000000027182
30. Yoshida M, Tateishi R, Hiroi S, Hongo Y, Fujiwara M, Kitanishi Y, Iwasaki K, Takeshima T, Igarashi A. Effects of Lusutrombopag on Post-Invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease. *Adv Ther* 2022;39(1): 379-90. Epub:2021/11/09 doi: 10.1007/s12325-021-01965-7
31. Nakagomi R, Tateishi R, Mikami S, Wake T, Kinoshita MN, Nakatsuka T, Minami T, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Shiina S, Koike K. Infectious Complications Related to Radiofrequency Ablation of Liver Tumors: The Role of Antibiotics. *PLoS One* 2021;16(11): e0259641. Epub:2021/11/20 doi: 10.1371/journal.pone.0259641

32. Nakatsuka T, Nakagawa H, Hayata Y, Wake T, Yamada T, Nishibatake Kinoshita M, Nakagomi R, Sato M, Minami T, Uchino K, Enooku K, Kudo Y, Tanaka Y, Kishikawa T, Otsuka M, Tateishi R, Koike K. Post-Treatment Cell-Free DNA as a Predictive Biomarker in Molecular-Targeted Therapy of Hepatocellular Carcinoma. *J Gastroenterol* 2021;56(5): 456-69. Epub:2021/03/14 doi: 10.1007/s00535-021-01773-4
33. Nakatsuka T, Tateishi R, Koike K. Changing Clinical Management of Nafld in Asia. *Liver Int* 2021. Epub:2021/08/31 doi: 10.1111/liv.15046
34. Sato M, Kobayashi T, Soroida Y, Tanaka T, Nakatsuka T, Nakagawa H, Nakamura A, Kurihara M, Endo M, Hikita H, Sato M, Gotoh H, Iwai T, Tateishi R, Koike K, Yatomi Y. Development of Novel Deep Multimodal Representation Learning-Based Model for the Differentiation of Liver Tumors on B-Mode Ultrasound Images. *J Gastroenterol Hepatol* 2022;37(4): 678-84. Epub:2021/12/16 doi: 10.1111/jgh.15763
35. Uchino K, Tateishi R, Wake T, Kinoshita MN, Nakagomi R, Nakatsuka T, Minami T, Sato M, Enooku K, Nakagawa H, Shiina S, Koike K. Radiofrequency Ablation of Liver Tumors in Patients on Antithrombotic Therapy: A Case-Control Analysis of over 10,000 Treatments. *J Vasc Interv Radiol* 2021;32(6): 869-77. Epub:2021/03/11 doi: 10.1016/j.jvir.2021.02.021
36. Yamada T, Minami T, Tateishi R, Koike K. Limited Efficacy of Atezolizumab and Bevacizumab for Hepatocellular Carcinoma Previously Treated with Tyrosine Kinase Inhibitor. *Liver Int* 2021;41(9): 2233-34. Epub:2021/07/22 doi: 10.1111/liv.15010
37. Kudo M, Ikeda M, Ueshima K, Sakamoto M, Shiina S, Tateishi R, Nouse K, Hasegawa K, Furuse J, Miyayama S, Murakami T, Yamashita T, Kokudo N. Response Evaluation Criteria in Cancer of the Liver Version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 Revised Version). *Hepatol Res* 2022;52(4): 329-36. Epub:2022/01/26 doi: 10.1111/hepr.13746
38. Nakatsuka T, Tateishi R, Nakagomi R, Minami T, Koike K. Risk Stratification of Hepatocellular Carcinoma after Hepatitis C Virus Eradication in Patients with Compensated Advanced Chronic Liver Disease in Japan. *J Hepatol* 2022. Epub:2022/03/16 doi:10.1016/j.jhep.2022.03.002

39. Nishida N, Yamakawa M, Shiina T, Mekada Y, Nishida M, Sakamoto N, Nishimura T, Iijima H, Hirai T, Takahashi K, Sato M, Tateishi R, Ogawa M, Mori H, Kitano M, Toyoda H, Ogawa C, Kudo M, investigators JAI. Artificial Intelligence (Ai) Models for the Ultrasonographic Diagnosis of Liver Tumors and Comparison of Diagnostic Accuracies between Ai and Human Experts. *J Gastroenterol* 2022;57(4): 309-21. Epub:2022/02/28 doi: 10.1007/s00535-022-01849-9
40. Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Kurosaki M, Ido A, Miki D, Yoshiji H, Takikawa Y, Sakamori R, Hiasa Y, Nakao K, Kato N, Ueno Y, Yatsuhashi H, Itoh Y, Tateishi R, Suda G, Takami T, Nakamoto Y, Asahina Y, Matsuura K, Yamashita T, Kanto T, Akuta N, Terai S, Shimizu M, Sobue S, Miyaki T, Moriuchi A, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T. Liver-Related Events after Direct-Acting Antiviral Therapy in Patients with Hepatitis C Virus-Associated Cirrhosis. *J Gastroenterol* 2022;57(2): 120-32. Epub:2022/01/22 doi: 10.1007/s00535-021-01845-5
41. Yoshida M, Tateishi R, Hiroi S, Fujiwara M, Kitanishi Y, Iwasaki K, Takeshima T, Igarashi A. Changes in Platelet Counts and Thrombocytopenia Risk in Patients with Chronic Liver Disease with Different Etiologies Using Real-World Japanese Data. *Adv Ther* 2022;39(2): 992-1003. Epub:2021/12/21 doi: 10.1007/s12325-021-02008-x
42. Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Kurosaki M, Ido A, Miki D, Yoshiji H, Takikawa Y, Sakamori R, Hiasa Y, Nakao K, Kato N, Ueno Y, Yatsuhashi H, Itoh Y, Tateishi R, Suda G, Takami T, Nakamoto Y, Asahina Y, Matsuura K, Yamashita T, Kanto T, Akuta N, Terai S, Shimizu M, Sobue S, Miyaki T, Moriuchi A, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T. Liver-Related Events after Direct-Acting Antiviral Therapy in Patients with Hepatitis C Virus-Associated Cirrhosis. *J Gastroenterol* 2022;57(2): 120-32. Epub:2022/01/22 doi: 10.1007/s00535-021-01845-5
43. Takayama T, Hasegawa K, Izumi N, Kudo M, Shimada M, Yamanaka N, Inomata M, Kaneko S, Nakayama H, Kawaguchi Y, Kashiwabara K, Tateishi R, Shiina S, Koike K, Matsuyama Y, Omata M, Makuuchi M, Kokudo N. Surgery Versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (Surf Trial). *Liver Cancer*

2022;11(3): 209–18. Epub:2022/08/12 doi: 10.1159/000521665

44. Hasegawa K, Takemura N, Yamashita T, Watadani T, Kaibori M, Kubo S, Shimada M, Nagano H, Hatano E, Aikata H, Iijima H, Ueshima K, Ohkawa K, Genda T, Tsuchiya K, Torimura T, Ikeda M, Furuse J, Akahane M, Kobayashi S, Sakurai H, Takeda A, Murakami T, Motosugi U, Matsuyama Y, Kudo M, Tateishi R, committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma TJ. Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 Version (5th Jsh-Hcc Guidelines). *Hepatol Res* 2023. Epub:2023/02/25 doi: 10.1111/hepr.13892
45. Nakatsuka T, Tateishi R, Sato M, Fujishiro M, Koike K. Agile Scores Are a Good Predictor of Liver-Related Events in Patients with Nafld. *J Hepatol* 2023. Epub:2023/03/05 doi: 10.1016/j.jhep.2023.02.029
46. Sato M, Akamatsu M, Shima T, Ikegami T, Yanase M, Mikami S, Imamura J, Nakatsuka T, Tateishi R, Yamauchi N, Ushiku T, Okanoue T, Fujishiro M, Hida E, Koike K. Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The Nash App Clinical Trial. *Am J Gastroenterol* 2023. Epub:2023/01/20 doi: 10.14309/ajg.0000000000002143
47. Wake T, Tateishi R, Moriyama M, Fukumoto T, Yamada T, Nakagomi R, Nakatsuka T, Sato M, Minami T, Uchino K, Nakagawa H, Shiina S, Koike K, Fujishiro M. Steroid Administration for Ischemic Complications after Radiofrequency Ablation: A Retrospective Study. *Hepatol Res* 2023. Epub:2023/02/23 doi: 10.1111/hepr.13891
48. Yamada T, Tateishi R, Iwai M, Tanaka M, Ijichi H, Sano M, Koike K, Todo T. Overcoming Resistance of Stroma-Rich Pancreatic Cancer with Focal Adhesion Kinase Inhibitor Combined with G47delta and Immune Checkpoint Inhibitors. *Mol Ther Oncolytics* 2023;28: 31-43. Epub:2023/01/10 doi: 10.1016/j.omto.2022.12.001
49. Shoji Kubo, Hiroji Shinkawa, Yoshinari Asaoka, Tatsuya Ioka, Hiroshi Igaki, Namiki Izumi, Takao Itoi, Michiaki Unno, Masayuki Ohtsuka, Takuji Okusaka, Masumi Kadoya, Masatoshi Kudo, Takashi Kumada, Norihiro Kokudo, Michiie Sakamoto, Yoshihiro Sakamoto, Hideyuki Sakurai, Tadatoshi Takayama, Osamu Nakashima, Yasushi Nagata, Etsuro Hatano, Kenichi Harada, Takamichi Murakami, Masakazu Yamamoto. Liver Cancer Study Group of Japan Clinical Practice Guidelines for

2) 学会発表

1. 佐藤雅哉, 建石良介, 小池和彦. 超音波Bモード画像での肝腫瘍性病変の良悪性識別におけるマルチモーダル深層学習の有用性の検討. 第107回日本消化器病学会総会 (2021年4月15日、東京)
2. 木下瑞希, 建石良介, 小池和彦. B型慢性肝炎患者における核酸アナログ治療と肝発癌に関する検討. 第107回日本消化器病学会総会 (2021年4月15日、東京)
3. 中塚拓馬, 小林玉宜, 揃田陽子, 中川勇人, 佐藤雅哉, 建石良介, 矢富裕, 小池和彦. 肝静脈波形の定量化を用いたNAFLDの簡便な肝線維化評価法. 日本超音波医学会第94回学術集会 (2021年5月21日、神戸)
4. 佐藤雅哉, 建石良介, 小池和彦. 肝疾患におけるビッグデータとAI(人工知能)の臨床応用 機械学習技術を用いたSVR後発癌予測アルゴリズムの有用性の検討. 第57回日本肝臓学会総会 (2021年6月18日、札幌)
5. 中込良, 建石良介, 森山慎, 福本剛, 山田友春, 和気泰次郎, 木下瑞希, 中塚拓馬, 佐藤雅哉, 南達也, 榎奥健一郎, 中川勇人, 小池和彦. C型肝炎SVR例における肝弾性値の推移と肝発癌. 第57回日本肝臓学会総会 (2021年6月18日、札幌)
6. 中塚拓馬, 建石良介, 小池和彦. 肝硬度測定値を用いたSVR後の肝発癌リスク分析 SVR後肝硬度低下は肝発癌リスク低減を示唆するか? 第25回日本肝臓学会大会 (2021年11月4日、神戸)
7. 佐藤雅哉, 建石良介, 小池和彦. 機械学習モデルを用いた肝細胞癌に対するラジオ波焼灼術後の再発予測の有用性の検討. 第25回日本肝臓学会大会 (2021年11月5日、神戸)
8. 浅岡良成, 建石良介, 山田康秀, 飯島尋子, 久保正二, 黒崎雅之, 椎名秀一朗, 中島収, 福本巧, 村上卓道, 坂元亨宇, 松山裕, 工藤正俊, 国土典宏. 肝癌薬物療法の実世界データを活用したオールジャパン研究—HERITAGE試験. 第25回肝がん分子標的治療研究会 (福岡) 2022
9. 浅岡良成, 松本康佑, 田村大和, 三浦亮, 有住俊彦, 相磯光彦, 田中篤. TACE・RFAで治療したTIPS施行後肝硬変・肝細胞癌の2例. 第40回Microwave Surgery研究会 (東京)
10. Yoshinari Asaoka, Yamato Tamura, Kosuke Matsumoto, Ryo Miura, Toshihiko Arizumi, Mitsuhiko Aiso and Atsushi Tanaka. Two HCC cases treated by TACE and RFA after TIPS for advanced cirrhosis with refractory ascites. ACTA 2021. Tokyo, Japan.
11. Yoshinari Asaoka. SVR & HCV-related HCC. APASL Oncology 2021. Tokyo, Japan.



12. Yoshinari Asaoka. Lenvatinib for intermediate stage HCC. APASL Oncology 2021. Tokyo, Japan.
13. 浅岡良成、建石良介、山田康秀、國土典宏. 第58回日本肝癌研究会 2022年5月12日 横浜 特別プログラム「肝癌データベース（全国原発性肝癌追跡調査）の現状と利活用における課題」
14. Yoshinari Asaoka, Ryosuke Tateishi, Yasuhide Yamada, Hiroko Iijima, Naoya Kato, Mitsuo Shimada, Etsuro Hatano, Takumi Fukumoto, Takamichi Murakami, Hirohisa Yano, Kengo Yoshimitsu, Masayuki Kurosaki, Michiie Sakamoto, Yutaka Matsuyama, Masatoshi Kudo, Norihiro Kokudo. 米国臨床腫瘍学会消化器がんシンポジウム2023 2023年1月20日 サンフランシスコ ポスター発表「Real World Data of Systemic therapy for Hepatocellular Carcinoma in Japan: HERITAGE.」
15. Y. Kawaguchi, R. Kita, T. Kimura, R. Goto, T. Takayama, N. Izumi, M. Kudo, S. Kaneko, N. Yamanaka, M. Inomata, M. Shimada, H. Baba, K. Koike, M. Omata, M. Makuuchi, Y. Matsuyama, Y. Yamada, N. Kokudo, K. Hasegawa. Medical expenditures and treatment efficacy of patients who had initial hepatocellular carcinoma and underwent surgery or radiofrequency ablation: Accompanying research of the SURF trial. 欧州臨床腫瘍学会 2022 パリ